As evidenced by our recent publications (13, 20), here, we further confirmed that SR9009 treatment impaired GBM cell proliferation, but LOX inhibition using BAPN had no such effect (Supplemental Figure 4, M–S). This evidence concerns the gene LOX and glioblastoma.